퓨쳐켐
Financials
Valuation Metrics
퓨쳐켐's Market Cap is ₩2224B. At end of 2025 it was ₩7709B. Ranked #760 of 2,410 in KR market (top 32%), #338 of 1,631 on KOSDAQ (top 21%), #84 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 36%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 222.43B KRW | KR#760/2,410 Sec#84/231 |
| Revenue | 20.59B KRW | KR#2,126/2,410 Sec#155/231 |
| Net Income | -11.09B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 68.41B KRW | KR#2,023/2,410 Sec#168/231 |
| Net Assets | 55.11B KRW | KR#1,841/2,410 Sec#155/231 |
| Employees | 87 | KR#1,746/2,410 Sec#139/231 |
| Value | ||
| P/B | 4.04x | KR#2,210/2,410 Sec#187/231 |
| P/S | 10.80x | KR#2,283/2,410 Sec#168/231 |
| FCF Yield | -1.11% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -20.12% | KR#2,088/2,410 Sec#162/231 |
| ROA | -16.21% | KR#2,199/2,410 Sec#168/231 |
| Op. Margin | -45.52% | KR#2,214/2,410 Sec#159/231 |
| Revenue Growth | 7.55% | KR#1,037/2,410 Sec#99/231 |
| Financial Health | ||
| Debt Ratio | 24.14% | KR#467/2,410 Sec#56/231 |
| Total Debt | 4.33B KRW | KR#1,803/2,410 Sec#175/231 |
| FCF | -2.47B KRW | KR#1,363/2,410 Sec#105/231 |
| Cash | 5.77B KRW | KR#1,957/2,410 Sec#178/231 |
| Current Ratio | 3.34x | KR#487/2,410 Sec#72/231 |
| Performance | ||
| 1Y Return | -54.70% | KR#2,039/2,410 Sec#183/231 |
| 1M Return | -0.14% | KR#285/2,410 Sec#31/231 |
| From 52W High | -74.60% | KR#2,196/2,410 Sec#197/231 |
| 1Y MDD | -79.13% | KR#2,263/2,410 Sec#200/231 |
| Trading | ||
| Volume | 147,103 shares | KR#420/2,410 Sec#47/231 |
| Trading Value | 1.05B KRW | KR#541/2,410 Sec#58/231 |
| Foreign Own. | 6.17% | KR#716/2,410 Sec#64/231 |
| Per Share | ||
| EPS | -358 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,779 KRW | KR#2,124/2,410 Sec#177/231 |
Company Info
FutureChem, a listed corporation, was established in 2001 to manufacture and sell radiopharmaceutical precursors, transferring its listing to the KOSDAQ Market in 2016 after a KONEX Market listing in 2015. The company develops, produces, and sells new radiopharmaceutical drugs, precursors, synthetic reagents, and automated synthesis devices, holding various pipelines including Alzavue for Alzheimer's diagnosis. Its affiliates are FutureChem Healthcare, SI Healthcare, and FutureChem U.S.A. FutureChem is headquartered in Seongdong-gu, Seoul.